Mineralys Therapeutics Inc [MLYS] stock is trading at $14.52, up 2.76%. An important factor to consider is whether the stock is rising or falling in short-term value. The MLYS shares have gain 11.69% over the last week, with a monthly amount glided 1.26%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Mineralys Therapeutics Inc [NASDAQ: MLYS] stock has seen the most recent analyst activity on June 11, 2025, when Jefferies initiated its Hold rating and assigned the stock a price target of $15. Previously, H.C. Wainwright started tracking the stock with Buy rating on July 10, 2024, and set its price target to $30. On April 02, 2024, Goldman initiated with a Buy rating and assigned a price target of $30 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $27 on March 07, 2023. Stifel initiated its recommendation with a Buy and recommended $45 as its price target on March 07, 2023. Guggenheim started tracking with a Buy rating for this stock on March 07, 2023, and assigned it a price target of $32. In a note dated March 07, 2023, Evercore ISI initiated an Outperform rating.
Mineralys Therapeutics Inc [MLYS] stock has fluctuated between $8.24 and $18.38 over the past year. Currently, Wall Street analysts expect the stock to reach $45 within the next 12 months. Mineralys Therapeutics Inc [NASDAQ: MLYS] shares were valued at $14.52 at the most recent close of the market. An investor can expect a potential return of 209.92% based on the average MLYS price forecast.
Analyzing the MLYS fundamentals
Gross Profit Margin for this corporation currently stands at -0.26% with Operating Profit Margin at -5972.53%, Pretax Profit Margin comes in at -5610.97%, and Net Profit Margin reading is -5610.97%. To continue investigating profitability, this company’s Return on Assets is posted at -0.57, Equity is -0.7 and Total Capital is -0.65.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.12 points at the first support level, and at 13.72 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.96, and for the 2nd resistance point, it is at 15.40.
Ratios To Look Out For
For context, Mineralys Therapeutics Inc’s Current Ratio is 15.12. On the other hand, the Quick Ratio is 15.12, and the Cash Ratio is 4.59.
Transactions by insiders
Recent insider trading involved Rodman David Malcom, Chief Medical Officer, that happened on Aug 13 ’25 when 11365.0 shares were sold. Officer, Rodman David Malcom completed a deal on Aug 13 ’25 to buy 11365.0 shares. Meanwhile, CFO and Secretary Levy Adam Scott sold 59925.0 shares on Jul 30 ’25.
